PFM Health Sciences’s Standard BioTools LAB Stock Holding History

PFM Health Sciences’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-980,505	Closed	-$3.52M	–	86
2022 Q1	$3.52M	Hold	980,505	–	–	0.13%	66
2021 Q4	$3.84M	Hold	980,505	–	–	0.13%	68
2021 Q3	$6.46M	Hold	980,505	–	–	0.19%	70
2021 Q2	$6.04M	Hold	980,505	–	–	0.19%	73
2021 Q1	$4.43M	Sell	980,505 -75,838	-7%	-$417K	0.14%	83
2020 Q4	$6.34M	Hold	1,056,343	–	–	0.22%	75
2020 Q3	$7.85M	Sell	1,056,343 -867,729	-45%	-$5.99M	0.36%	67
2020 Q2	$7.72M	Sell	1,924,072 -749,018	-28%	-$2.61M	0.4%	67
2020 Q1	$6.79M	Sell	2,673,090 -561,894	-17%	-$1.85M	0.56%	49
2019 Q4	$11.3M	Buy	3,234,984 +125,805	+4%	+$443K	0.54%	45
2019 Q3	$14.4M	Buy	3,109,179 +1,732,922	+126%	+$13.6M	0.43%	53
2019 Q2	$17M	Sell	1,376,257 -65,106	-5%	-$829K	0.32%	69
2019 Q1	$19.2M	Buy	+1,441,363	New	+$15.2M	0.42%	66

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PFM Health Sciences's LAB Position: Q2 2022 in Review

PFM Health Sciences sold out of Standard BioTools (LAB) in Q2 2022, closing a stake of 980,505 shares — an estimated $3.52M sold.

PFM Health Sciences first reported a position in LAB in Q1 2019 and held it in 13 quarters. The position peaked at $19.2M in Q1 2019. 86 funds tracked by Wall St. Rank hold LAB as of Q2 2022.

PFM Health Sciences reported no remaining Standard BioTools position as of Q2 2022 after selling out during the quarter.
PFM Health Sciences sold 980,505 Standard BioTools shares in Q2 2022, an estimated $3.52M.
PFM Health Sciences first reported a position in Standard BioTools in Q1 2019 and held it in 13 quarters.
PFM Health Sciences's Standard BioTools position peaked at $19.2M in Q1 2019.
86 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2022.

Based on PFM Health Sciences's 13F filing for Q2 2022, filed 15 Aug 2022.